Pharmacokinetics of anti-D IgG in pregnant RhD-negative women
Article first published online: 22 DEC 2003
BJOG: An International Journal of Obstetrics & Gynaecology
Volume 110, Issue 1, pages 39–45, January 2003
How to Cite
Bichler, J., Schöndorfer, G., Pabst, G. and Andresen, I. (2003), Pharmacokinetics of anti-D IgG in pregnant RhD-negative women. BJOG: An International Journal of Obstetrics & Gynaecology, 110: 39–45. doi: 10.1046/j.1471-0528.2003.02158.x
- Issue published online: 22 DEC 2003
- Article first published online: 22 DEC 2003
- Accepted 27 September 2002
Objective To assess the pharmacokinetics of anti-D IgG in pregnant Rhesus D-negative women after intramuscular and intravenous administration of 300 μg of Rhophylac.
Design An open, randomised, multicentre study.
Setting Seven gynaecological practices in Germany.
Sample Fourteen RhD-negative pregnant women at risk of becoming Rhesus D immunised received study drug at 28th week of pregnancy either by intramuscular or intravenous route.
Main outcome measures Anti-D IgG concentrations of serum samples obtained up to 11 weeks following antenatal Rhesus D prophylaxis were quantified by flow cytometry.
Results Mean anti-D IgG concentrations after intravenous and intramuscular administration differed up to seven days post-injection, from two weeks onwards they were comparable to each other. Irrespective of the administration route, anti-D IgG in serum was detectable in all women up to at least nine weeks post-administration.
Conclusions The serum concentrations of anti-D IgG measured after administration of Rhophylac were very similar to those obtained with 300 μg of a different anti-D immunoglobulin product.